EP4705281A1 - Verbindungen zur behandlung von krebs - Google Patents
Verbindungen zur behandlung von krebsInfo
- Publication number
- EP4705281A1 EP4705281A1 EP24729464.8A EP24729464A EP4705281A1 EP 4705281 A1 EP4705281 A1 EP 4705281A1 EP 24729464 A EP24729464 A EP 24729464A EP 4705281 A1 EP4705281 A1 EP 4705281A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- alkyl
- optionally substituted
- compound
- independently selected
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363463353P | 2023-05-02 | 2023-05-02 | |
| PCT/US2024/027254 WO2024229121A1 (en) | 2023-05-02 | 2024-05-01 | Compounds for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP4705281A1 true EP4705281A1 (de) | 2026-03-11 |
Family
ID=91302196
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP24729464.8A Pending EP4705281A1 (de) | 2023-05-02 | 2024-05-01 | Verbindungen zur behandlung von krebs |
Country Status (2)
| Country | Link |
|---|---|
| EP (1) | EP4705281A1 (de) |
| WO (1) | WO2024229121A1 (de) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009072581A1 (ja) * | 2007-12-05 | 2009-06-11 | Aska Pharmaceutical Co., Ltd. | ラクタム化合物又はその塩及びｐｐａｒ活性化剤 |
| WO2017075394A1 (en) * | 2015-10-29 | 2017-05-04 | Effector Therapeutics, Inc. | Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of mnk1 and mnk2 |
| CN113004145A (zh) | 2021-03-24 | 2021-06-22 | 阿里生物新材料（常州）有限公司 | 一种3-溴-2,5-二甲基苯甲酸甲酯的合成方法 |
-
2024
- 2024-05-01 EP EP24729464.8A patent/EP4705281A1/de active Pending
- 2024-05-01 WO PCT/US2024/027254 patent/WO2024229121A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024229121A1 (en) | 2024-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2024229121A1 (en) | Compounds for treating cancer | |
| EP3601239B1 (de) | Neuartige, als shp2-inhibitoren nützliche heterocyclische derivate | |
| AU2016204879B2 (en) | CDK Inhibitors | |
| TW202409030A (zh) | 五元並六元含氮化物、其中間體、製備方法和應用 | |
| CN116003321A (zh) | 可用作shp2抑制剂的新型杂环衍生物 | |
| KR20200120713A (ko) | 피리미딘-융합고리 화합물 및 그의 제조방법과 용도 | |
| CN116888108A (zh) | 新型egfr降解剂 | |
| NZ749946A (en) | Novel compound or pharmaceutically acceptable salt thereof | |
| CN116813647B (zh) | 一类含氮稠环类sting调节剂类化合物、制备方法和用途 | |
| CN116323562B (zh) | 一类具有激酶抑制活性的化合物 | |
| TW202334167A (zh) | 作為ｅｒｂｂ２抑制劑之稠合四環喹唑啉衍生物 | |
| WO2024081904A1 (en) | Methods for treating cancer | |
| CA3201540A1 (en) | Aromatic heterocyclic compound, pharmaceutical composition and use thereof | |
| RS66733B1 (sr) | Inhibitori alfa v beta6 integrina | |
| CA3145344A1 (en) | Pyrazolopyrimidine compound, preparation method for same and applications thereof | |
| JP2020505397A (ja) | Ｌｒｒｋ２キナーゼ活性を阻害するための化合物 | |
| WO2024054512A1 (en) | Akt1 modulators | |
| WO2022253309A1 (zh) | 取代的杂环化合物及其应用 | |
| CA3227713A1 (en) | 8-oxa-3-azabicyclo[3.2.1]octane compounds or salt thereof, and preparation method and use thereof | |
| CN110655520A (zh) | 嘧啶并环化合物及其制备方法和应用 | |
| TW202309006A (zh) | 作為ｓｉｇｍａ配體的新穎吡啶磺醯胺衍生物、其製備方法及用途，以及包含該吡啶－磺醯胺衍生物的醫藥組成物 | |
| EP4602043A1 (de) | 4h-pyrido[1,2-a pyrimidin-4-on-derivate zur behandlung von krebs | |
| TW202345794A (zh) | 依莫帕米結合蛋白抑制劑及其用途 | |
| KR20240150419A (ko) | 아릴설폰아미드 화합물 | |
| KR20240021758A (ko) | 시그마 리간드로서 신규 피라졸로[1,5-a]피리미딘 유도체 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20251114 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR |